SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California.
The corporate presentation will review the Company accomplishments in 2011, as well as outline the corporate plans for 2012 and beyond.
Specifically, the Company will discuss the recent very productive Type C meeting that was held with the FDA on elagolix for endometriosis, one of the outcomes of which was the decision to file a Special Protocol Assessment (SPA) with the FDA. The expected NDA filing of elagolix for the treatment of endometriosis is in 2015.
Additionally, the presentation will cover the Company's VMAT2 program for movement disorders, including the status of the current Phase II study assessing the impact of NBI-98854 in patients with tardive dyskinesia. This study, which began in the fall of 2011, has recently completed enrollment and will report top-line data in the first quarter of 2012. The Company also recently received a notification of allowable claims for its NBI-98854 European Patent Application from the European Patent Office, and has begun planning for larger Phase IIb trials, to be launched in mid-2012, for up to three months of continuous treatment with NBI-98854.
The live presentation takes place on Thursday, January 12, 2012 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A copy of the presentation materials will be filed with the Securities and Exchange Commission on or before Monday, January 9, 2012.
If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved